Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG141 (Narecovir) Phase 1b in Chronic Hepatitis B
NCT04868981Phase 1Completed
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of narecovir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Fujian Cosunter Pharmaceutical Co., Ltd. Primary endpoints: Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities up to 33 days, Maximum Plasma Concentration (Cmax) of GST-HG141 at Day 28 and 3 more. Started May 2021; status: completed.
02
Drugs
narecovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04868981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868981.